The answer so far

There is no established human evidence that using BPC-157 near an injury works better than using it elsewhere. Animal route studies and small human reports ask different questions; none establishes that a capsule, skin product and injection are interchangeable or that any of them repairs a particular injury.124

On this page
  1. Why do people talk about “local” and “systemic”?
  2. Does BPC-157 have to be used near an injury?
  3. What do animal studies tell us?
  4. Does finding a signal in the body prove an effect?
  5. Are capsules, creams and injections interchangeable?
  6. What research might make the answer clearer?
  7. What should someone with an injury do now?
  8. Sources
LINKED BUILDING BLOCKSAmino acids joined into a chainSequence and structure both matter
Conceptual schematic. Simplified and not to scale; not a scan, microscopy image or validated simulation.

Why do people talk about “local” and “systemic”?

A local effect is one that happens in a particular area; a systemic effect involves the wider body, often after a substance enters the circulation. These are useful descriptions, not guarantees about where a product stays or what it does. An injury has its own location and biology; a product may move, change or break down after it is used. For the bigger picture, start with what BPC-157 is and why people discuss it.1

Does BPC-157 have to be used near an injury?

There is no established answer for human injury recovery. The small human knee report involved a joint, not a comparison of injection locations, and it did not show tissue repair on follow-up imaging. It cannot tell us whether putting a product near an injury works better than using it elsewhere. The question requires a controlled study of the same defined product, injury and meaningful recovery outcomes. Read what the human reports did and did not measure.41

What do animal studies tell us?

In a rat experiment on a surgically cut knee ligament, researchers reported healing-related outcomes with several experimental routes, including a topical preparation and an oral preparation. This raises questions for further research; a rat injury, its experimental products and their routes are not evidence that a human capsule or skin product reaches a human injury or improves recovery. The rat Achilles study is another example of why injury model and outcome matter.26

From capsule to possible effectThese are questions to investigate, not measurements of a particular product.
  • ReleaseDoes the particular formulation release the peptide where expected?
  • StabilityHow much remains intact under the conditions being studied?
  • Absorption or local actionDoes it reach the blood, or is a local gut effect the question?
  • OutcomeDoes the tested product make a meaningful difference in people, and what harms occur?

Does finding a signal in the body prove an effect?

In separate pharmacokinetic research—studies of what the body does to a substance—researchers measured BPC-157 after injection in rats and dogs and followed a radioactive label in rat tissues. The peptide was also broken into smaller fragments. A radioactive signal does not by itself establish how much intact, biologically active peptide reaches an injured human tendon, or whether it helps the person recover. Animal measurements are informative, but they do not establish a human dose, route or duration.31

Are capsules, creams and injections interchangeable?

No. A product’s formulation and route affect what happens before it can reach a tissue: an oral product encounters digestion and absorption; a skin product has to cross skin; an injected product has different exposure and quality requirements. The FDA’s July 2026 review described important gaps in human pharmacokinetic information for nominated routes. That does not prove a particular route cannot work; it means these products cannot be assumed equivalent. A label or seller claim is not a measurement in your body. For practical quality questions, see storage, identity and sterility. The early ulcerative-colitis report used a different formulation: see what it found and did not establish. For the separate oral-versus-injection question, see the route comparison.13

What research might make the answer clearer?

A registry listing describes a possible BPC-157 hamstring study, but we cannot verify it is operating: other entries naming the same sponsor and site call themselves fictional or mock. The hamstring entry does not itself say this. We previously described it as a planned trial; that overstated what the record establishes. A future verified comparison would still apply first to its specific product, route and injury. See the human-evidence guide for other records and their limitations.589

What should someone with an injury do now?

A clinician or physiotherapist can help assess the injury and discuss an appropriate recovery plan. The reason for pain and the urgency of assessment differ between injuries. If someone develops a concerning reaction after an injection, our guide explains signs that need prompt medical attention. If competing in tested sport, check the applicable anti-doping rules.17

Sources, kept close.

Selected supporting sources; this is not a complete literature review.

  1. July 23–24, 2026 Pharmacy Compounding Advisory Committee briefing materialsU.S. Food and Drug Administration · Regulator briefing; adverse-event reports and evidence limitationsAccessed 2026-11-03 · Source date: 2026-07-23
  2. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the ratJournal of Orthopaedic Research / PubMed · Primary animal study, abstractAccess checked 2026-11-05 · Source date: 2010 · Surgically severed rat knee ligament; experimental oral and topical routes among others. Not evidence for human product effectiveness or route equivalence.
  3. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogsFrontiers in Pharmacology / PubMed · Primary animal pharmacokinetic study, abstract and figuresAccess checked 2026-11-06 · Source date: 2022 · Rats and dogs, intravenous and intramuscular exposure; radiolabel in rat tissue may include metabolites. Does not establish intact exposure or recovery in humans.
  4. Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainLee and Padgett / Alternative Therapies in Health and Medicine · Published retrospective uncontrolled case series; full report inspectedAccess checked 2026-11-05 · Source date: 2021 · Full paper: 16/17 contacted, 12 received BPC-157 alone and four also received thymosin beta-4; recall-based, no control, no follow-up MRI; patients paid.
  5. BPC 157 for Acute Hamstring Muscle Strain RepairClinicalTrials.gov / US National Library of Medicine · Sponsor-submitted registry listing; operation unverifiedAccess checked 2026-11-05 · Record lists Hudson Biotech and the same site as other records explicitly labelled fictional or mock; this entry does not label itself that way. No independent confirmation of operation; no results posted when checked.
  6. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendonJournal of Orthopaedic Research / PubMed · Original rat tendon and cell study; abstract reviewedAccessed 2026-11-05 · Source date: 2003
  7. CellulitisNHS · Official clinical guidanceAccessed 2026-11-07
  8. TB-500 cardiovascular biomarkers listing (NCT07487363)ClinicalTrials.gov / U.S. National Library of Medicine · Sponsor-submitted registry record explicitly described as fictionalAccess checked 2026-11-05 · Source date: 2026-03-23 · The sponsor-submitted summary calls this record fictional; same sponsor and site as two other peptide listings. That association alone does not establish whether either other listing is fictional.
  9. Tesamorelin liver-fat listing: mock study (NCT07481734)ClinicalTrials.gov / U.S. National Library of Medicine · Sponsor-submitted registry record explicitly titled mock studyAccess checked 2026-11-05 · Source date: 2026-03-19 · Sponsor-submitted title calls this a mock study; same sponsor and site as two other peptide listings. It does not establish whether either other listing is fictional.

The next useful question.

Substance profile

BPC-157.

A plain-language evidence-gap profile: what BPC-157 is, what laboratory studies suggest, and how little human evidence exists.

9 min read